Probiotics and Early Microbial Contact in Preterm Neonates

NCT ID: NCT01454661

Last Updated: 2018-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2019-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Probiotics are live microbes which, when administered in sufficient amounts, confer a health benefit to the host. According to recent clinical trials, administration of probiotics to very low birth weight infants significantly reduces overall mortality and risk of necrotizing enterocolitis, a devastating inflammatory intestinal disease. The investigators have previously demonstrated that administering probiotics to the lactating mother enhances the immunoprotective properties of breast milk. Despite the promising data, the optimal probiotic intervention is yet to be established. The mechanisms by which probiotics exert their effects remain largely unknown.

This research project is based on the notion that modulation of early microbial contact by probiotics may provide a safe and effective means to improve the health of preterm infants. In particular, the investigators hypothesize that the protective potential of probiotics may be enhanced via breast milk by administering probiotics to the lactating mother. All of the potentially beneficial effects of probiotic bacteria are strain-specific and therefore preliminary laboratory and clinical research with regard to different physiological targets of probiotic intervention should be carried out to guide the design of large-scale clinical trials aiming show clinical efficacy and establish clinical practice. The purpose of this research project is to identify targets for probiotic therapy in premature neonates and to provide insight into the optimal probiotic strains and administration protocol the clinical efficacy of which will subsequently be tested in a randomized controlled trial.

The specific aims of the project are:

1. To determine the effect of maternal consumption of probiotics during lactation on immunomodulatory properties of breast milk in mothers of premature infants. Concentrations of immunomodulatory factors and microbiological properties of breast milk will be measured.
2. To investigate the impact of different probiotic administration protocols on gut microbiota composition in preterm infants. In particular, the issue whether maternal probiotic consumption instead or in addition to probiotics administered to the infant is effective will be elucidated. Different potential probiotic strains will be assessed.
3. To elucidate the impact probiotic bacteria administered to the lactating mother and/or directly to the infant on gut immunophysiology in preterm infants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premature; Infant, Light-for-dates Breastfeeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo mother - LGG infant

Placebo is administered to the lactating mother whilst the infant receives the probiotic LGG.

Group Type ACTIVE_COMPARATOR

LGG

Intervention Type DIETARY_SUPPLEMENT

Lactobacillus rhamnosus GG 10E9 cfu / day

placebo mother - placebo infant

Placebo is administered to both the lactating mother and her infant.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Microcrystalline cellulose is used as placebo.

LGG mother - placebo infant

The probiotic LGG is administered to the lactating mother whilst the infant receives placebo.

Group Type ACTIVE_COMPARATOR

LGG

Intervention Type DIETARY_SUPPLEMENT

Lactobacillus rhamnosus GG 10E9 cfu / day

LGG+Bb-12 mother - Placebo infant

A combination of the probiotics LGG and Bb-12 is administered to the lactating mother, the infant receives placebo.

Group Type ACTIVE_COMPARATOR

LGG+Bb-12

Intervention Type DIETARY_SUPPLEMENT

A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.

Pacebo mother - LGG+Bb-12 infant

Placebo is administered to the lactating mother, the infant receives a combination of the probiotics LGG and Bb-12

Group Type ACTIVE_COMPARATOR

LGG+Bb-12

Intervention Type DIETARY_SUPPLEMENT

A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LGG

Lactobacillus rhamnosus GG 10E9 cfu / day

Intervention Type DIETARY_SUPPLEMENT

LGG+Bb-12

A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Microcrystalline cellulose is used as placebo.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* premature infant born at \<35 weeks gestational age

Exclusion Criteria

* severe asphyxia
* significant anomalies
Maximum Eligible Age

3 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Turku

OTHER

Sponsor Role collaborator

Massachusetts General Hospital

OTHER

Sponsor Role collaborator

Turku University Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Samuli Rautava

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Samuli Rautava, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Turku University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Turku University Hospital

Turku, , Finland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Finland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Samuli Rautava, MD, PhD

Role: CONTACT

+358 40 7033166

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Samuli Rautava, MD, PhD

Role: primary

+358 40 7033166

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ETMK 104/180/2011

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prebiotic in Preterm Infants
NCT03306316 COMPLETED NA
Probiotics/TPN in the NICU
NCT04977817 COMPLETED
Efficacy of a Dietary Supplement in Infants
NCT07341477 NOT_YET_RECRUITING NA